For example, on the basis of the promising clinical activity observed in the KEYNOTE-059 trial, pembrolizumab was approved for the treatment of patients with chemotherapy-refractory PD-L1–positive GC/GEJC cancer (5). This evidence concerns the gene CD274 and cancer.